| Description |
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) study will assess the efficacy and safety of durvalumab and olaparib when added to standard of care (SoC) in patients with newly diagnosed advanced ovarian cancer. The study consists of 2 independent cohorts which are defined by the breast cancer sensitivity gene (BRCA) mutated (BRCAm) status, based on testing of tumour tissue (ie, tBRCAm status) of the patients. |
